Synthetic retinoid am80 ameliorates lung and arthritic autoimmune responses by inhibiting t follicular helper and th17 cell responses

Debdut Naskar, Fei Teng, Krysta M. Felix, C. Pierce Bradley, Hsin-Jung Joyce Wu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Rheumatoid arthritis is an autoimmune disorder that affects the joints and other organs. Pulmonary complications contribute significantly to rheumatoid arthritis mortality. Retinoic acid and its synthetic compound AM80 play roles in immunoregulation but their effect on mucosal autoimmunity remains largely unknown. T follicular helper (Tfh) and Th17 cells are known to promote inflammation and autoantibody production. Using the K/BxN autoimmune arthritis model, we elucidate a novel mechanism whereby oral AM80 administration suppressed lung mucosa-associated Tfh and autoantibody responses by increasing the guthoming a4b7 integrin expression on Tfh cells. This diverted Tfh cells from systemic (non-gut) inflamed sites such as the lung into the gut-associated lymphoid tissues, Peyer's patches, and thus reduced the systemic autoantibodies. AM80 also inhibited the lung Th17 response. AM80's effect in the lungs was readily applied to the joints as AM80 also inhibited Tfh and Th17 responses in the spleen, the major autoantibody producing site known to correlate with K/BxN arthritis severity. Finally, we used anti-b7 treatment as an alternative approach, demonstrating that manipulating T cell migration between the gut and systemic sites alters the systemic disease outcome. The b7 blockade prevented both Tfh and Th17 cells from entering the non-immunopathogenic site, the gut, and retained these Teffector cells in the systemic sites, leading to augmented arthritis. These data suggest a dual beneficial effect of AM80, targeting both Tfh and Th17 cells, and warrant strict safety monitoring of gut-homing perturbing agents used in treating intestinal inflammation.

Original languageEnglish (US)
Pages (from-to)1855-1864
Number of pages10
JournalJournal of Immunology
Volume198
Issue number5
DOIs
StatePublished - Mar 1 2017

Fingerprint

Th17 Cells
Retinoids
Helper-Inducer T-Lymphocytes
Autoimmunity
Arthritis
Autoantibodies
Lung
Rheumatoid Arthritis
Joints
Inflammation
Peyer's Patches
Lymphoid Tissue
Tretinoin
Integrins
Cell Movement
Oral Administration
tamibarotene
Mucous Membrane
Spleen
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Synthetic retinoid am80 ameliorates lung and arthritic autoimmune responses by inhibiting t follicular helper and th17 cell responses. / Naskar, Debdut; Teng, Fei; Felix, Krysta M.; Bradley, C. Pierce; Wu, Hsin-Jung Joyce.

In: Journal of Immunology, Vol. 198, No. 5, 01.03.2017, p. 1855-1864.

Research output: Contribution to journalArticle

@article{605eb31683474835a2ea984ea2413195,
title = "Synthetic retinoid am80 ameliorates lung and arthritic autoimmune responses by inhibiting t follicular helper and th17 cell responses",
abstract = "Rheumatoid arthritis is an autoimmune disorder that affects the joints and other organs. Pulmonary complications contribute significantly to rheumatoid arthritis mortality. Retinoic acid and its synthetic compound AM80 play roles in immunoregulation but their effect on mucosal autoimmunity remains largely unknown. T follicular helper (Tfh) and Th17 cells are known to promote inflammation and autoantibody production. Using the K/BxN autoimmune arthritis model, we elucidate a novel mechanism whereby oral AM80 administration suppressed lung mucosa-associated Tfh and autoantibody responses by increasing the guthoming a4b7 integrin expression on Tfh cells. This diverted Tfh cells from systemic (non-gut) inflamed sites such as the lung into the gut-associated lymphoid tissues, Peyer's patches, and thus reduced the systemic autoantibodies. AM80 also inhibited the lung Th17 response. AM80's effect in the lungs was readily applied to the joints as AM80 also inhibited Tfh and Th17 responses in the spleen, the major autoantibody producing site known to correlate with K/BxN arthritis severity. Finally, we used anti-b7 treatment as an alternative approach, demonstrating that manipulating T cell migration between the gut and systemic sites alters the systemic disease outcome. The b7 blockade prevented both Tfh and Th17 cells from entering the non-immunopathogenic site, the gut, and retained these Teffector cells in the systemic sites, leading to augmented arthritis. These data suggest a dual beneficial effect of AM80, targeting both Tfh and Th17 cells, and warrant strict safety monitoring of gut-homing perturbing agents used in treating intestinal inflammation.",
author = "Debdut Naskar and Fei Teng and Felix, {Krysta M.} and Bradley, {C. Pierce} and Wu, {Hsin-Jung Joyce}",
year = "2017",
month = "3",
day = "1",
doi = "10.4049/jimmunol.1601776",
language = "English (US)",
volume = "198",
pages = "1855--1864",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Synthetic retinoid am80 ameliorates lung and arthritic autoimmune responses by inhibiting t follicular helper and th17 cell responses

AU - Naskar, Debdut

AU - Teng, Fei

AU - Felix, Krysta M.

AU - Bradley, C. Pierce

AU - Wu, Hsin-Jung Joyce

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Rheumatoid arthritis is an autoimmune disorder that affects the joints and other organs. Pulmonary complications contribute significantly to rheumatoid arthritis mortality. Retinoic acid and its synthetic compound AM80 play roles in immunoregulation but their effect on mucosal autoimmunity remains largely unknown. T follicular helper (Tfh) and Th17 cells are known to promote inflammation and autoantibody production. Using the K/BxN autoimmune arthritis model, we elucidate a novel mechanism whereby oral AM80 administration suppressed lung mucosa-associated Tfh and autoantibody responses by increasing the guthoming a4b7 integrin expression on Tfh cells. This diverted Tfh cells from systemic (non-gut) inflamed sites such as the lung into the gut-associated lymphoid tissues, Peyer's patches, and thus reduced the systemic autoantibodies. AM80 also inhibited the lung Th17 response. AM80's effect in the lungs was readily applied to the joints as AM80 also inhibited Tfh and Th17 responses in the spleen, the major autoantibody producing site known to correlate with K/BxN arthritis severity. Finally, we used anti-b7 treatment as an alternative approach, demonstrating that manipulating T cell migration between the gut and systemic sites alters the systemic disease outcome. The b7 blockade prevented both Tfh and Th17 cells from entering the non-immunopathogenic site, the gut, and retained these Teffector cells in the systemic sites, leading to augmented arthritis. These data suggest a dual beneficial effect of AM80, targeting both Tfh and Th17 cells, and warrant strict safety monitoring of gut-homing perturbing agents used in treating intestinal inflammation.

AB - Rheumatoid arthritis is an autoimmune disorder that affects the joints and other organs. Pulmonary complications contribute significantly to rheumatoid arthritis mortality. Retinoic acid and its synthetic compound AM80 play roles in immunoregulation but their effect on mucosal autoimmunity remains largely unknown. T follicular helper (Tfh) and Th17 cells are known to promote inflammation and autoantibody production. Using the K/BxN autoimmune arthritis model, we elucidate a novel mechanism whereby oral AM80 administration suppressed lung mucosa-associated Tfh and autoantibody responses by increasing the guthoming a4b7 integrin expression on Tfh cells. This diverted Tfh cells from systemic (non-gut) inflamed sites such as the lung into the gut-associated lymphoid tissues, Peyer's patches, and thus reduced the systemic autoantibodies. AM80 also inhibited the lung Th17 response. AM80's effect in the lungs was readily applied to the joints as AM80 also inhibited Tfh and Th17 responses in the spleen, the major autoantibody producing site known to correlate with K/BxN arthritis severity. Finally, we used anti-b7 treatment as an alternative approach, demonstrating that manipulating T cell migration between the gut and systemic sites alters the systemic disease outcome. The b7 blockade prevented both Tfh and Th17 cells from entering the non-immunopathogenic site, the gut, and retained these Teffector cells in the systemic sites, leading to augmented arthritis. These data suggest a dual beneficial effect of AM80, targeting both Tfh and Th17 cells, and warrant strict safety monitoring of gut-homing perturbing agents used in treating intestinal inflammation.

UR - http://www.scopus.com/inward/record.url?scp=85014967801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014967801&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1601776

DO - 10.4049/jimmunol.1601776

M3 - Article

C2 - 28130500

AN - SCOPUS:85014967801

VL - 198

SP - 1855

EP - 1864

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -